Apr 23, 2007 β Rheologics Technologies Inc., a company that studies blood viscosity and its relationship to cardiovascular disease, has announced plans for a multicenter clinical study on the variability of whole blood viscosity.
Whole blood viscosity has been studied for over 30 years with approximately 1,000 papers published in peer-reviewed journals during that time period. This body of research has correlated whole blood viscosity to numerous disease conditions such as coronary and carotid artery disease as well as every major cardiac risk factor, including blood pressure, LDL cholesterol, C-reactive protein, age, and type-II diabetes.
With respect to this body of published work, Rheologics is responding to a need for establishing standards for healthy ranges for whole blood viscosity and a clearer understanding of the variability of whole blood viscosity in a broad cross-section of patients.
For more information visit www.rheologics.com.
October 09, 2019 
